{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T23:40:18Z","timestamp":1740786018459,"version":"3.38.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.7759\/cureus.79849","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:58:11Z","timestamp":1740783491000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Impact: The Damage Index for Antiphospholipid Syndrome in the Context of Other Autoimmune Diseases and Cardiovascular Risk Factors"],"prefix":"10.7759","author":[{"given":"Jo\u00e3o","family":"Faia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eul\u00e1lia","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Luisa","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Bem Haja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziela","family":"Carvalheiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou MG","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019, 78:1296-304. 10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz-Irastorza G","year":"2004","unstructured":"Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004, 164:77-82. 10.1001\/archinte.164.1.77","journal-title":"Arch Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera R","year":"2015","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, et al.. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015, 74:1011-8. 10.1136\/annrheumdis-2013-204838","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315576858","article-title":"Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)","volume":"24","author":"Amigo MC","year":"2015","unstructured":"Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barrag\u00e1n-Garfias JA, Vargas A, Jara LJ. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015, 24:927-34. 10.1177\/0961203315576858","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109727","article-title":"Assessing disease activity and damage in antiphospholipid syndrome","volume":"255","author":"Andrade D","year":"2023","unstructured":"Andrade D, Tektonidou MG. Assessing disease activity and damage in antiphospholipid syndrome. Clin Immunol. 2023, 255:109727. 10.1016\/j.clim.2023.109727","journal-title":"Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman D","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, et al.. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996, 39:363-9. 10.1002\/art.1780390303","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320901598","article-title":"Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus","volume":"29","author":"Torricelli AK","year":"2020","unstructured":"Torricelli AK, Ugolini-Lopes MR, Bonf\u00e1 E, Andrade D. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus. 2020, 29:256-62. 10.1177\/0961203320901598","journal-title":"Lupus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241246360","article-title":"Predictors of damage accrual and its impact on health-related quality of life of thrombotic antiphospholipid syndrome: Independent validation of the damage index for antiphospholipid syndrome (DIAPS)","volume":"33","author":"Gaspar P","year":"2024","unstructured":"Gaspar P, Fernandes AS, Abrantes AM, et al.. Predictors of damage accrual and its impact on health-related quality of life of thrombotic antiphospholipid syndrome: Independent validation of the damage index for antiphospholipid syndrome (DIAPS). Lupus. 2024, 33:716-27. 10.1177\/09612033241246360","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/0gs167","article-title":"A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome","volume":"41","author":"Gaspar P","year":"2023","unstructured":"Gaspar P, Farinha F, Sayar Z, Efthymiou M, Cohen H, Isenberg DA. A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome. Clin Exp Rheumatol. 2023, 41:605-12. 10.55563\/clinexprheumatol\/0gs167","journal-title":"Clin Exp Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221079781","article-title":"Description of damage in different clusters of patients with antiphospholipid syndrome","volume":"31","author":"Uluda\u011f \u00d6","year":"2022","unstructured":"Uluda\u011f \u00d6, \u00c7ene E, Gurel E, et al.. Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus. 2022, 31:433-42. 10.1177\/09612033221079781","journal-title":"Lupus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.07.004","article-title":"Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS)","volume":"92","author":"Radin M","year":"2021","unstructured":"Radin M, Foddai SG, Cecchi I, Roccatello D, Sciascia S. Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). Eur J Intern Med. 2021, 92:134-6. 10.1016\/j.ejim.2021.07.004","journal-title":"Eur J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2019.01.004","article-title":"Angiotensin II and vascular damage in hypertension: role of oxidative stress and sympathetic activation","volume":"115","author":"Masi S","year":"2019","unstructured":"Masi S, Uliana M, Virdis A. Angiotensin II and vascular damage in hypertension: role of oxidative stress and sympathetic activation. Vascul Pharmacol. 2019, 115:13-7. 10.1016\/j.vph.2019.01.004","journal-title":"Vascul Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.01.013","article-title":"Inflammation in hypertension","volume":"36","author":"Xiao L","year":"2020","unstructured":"Xiao L, Harrison DG. Inflammation in hypertension. Can J Cardiol. 2020, 36:635-47. 10.1016\/j.cjca.2020.01.013","journal-title":"Can J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091293","article-title":"Endothelial function in dyslipidemia: roles of LDL-cholesterol, HDL-cholesterol and triglycerides","volume":"12","author":"Higashi Y","year":"2023","unstructured":"Higashi Y. Endothelial function in dyslipidemia: roles of LDL-cholesterol, HDL-cholesterol and triglycerides. Cells. 2023, 12:1293. 10.3390\/cells12091293","journal-title":"Cells"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1359255","article-title":"Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications","volume":"15","author":"Yang DR","year":"2024","unstructured":"Yang DR, Wang MY, Zhang CL, Wang Y. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. Front Endocrinol. 2024, 15:1359255. 10.3389\/fendo.2024.1359255","journal-title":"Front Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead292","article-title":"Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry","volume":"63","author":"Balbi GG","year":"2024","unstructured":"Balbi GG, Ahmadzadeh Y, Tektonidou MG, et al.. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry. Rheumatology. 2024, 63:772-9. 10.1093\/rheumatology\/kead292","journal-title":"Rheumatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341728-assessing-the-impact-the-damage-index-for-antiphospholipid-syndrome-in-the-context-of-other-autoimmune-diseases-and-cardiovascular-risk-factors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:58:13Z","timestamp":1740783493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341728-assessing-the-impact-the-damage-index-for-antiphospholipid-syndrome-in-the-context-of-other-autoimmune-diseases-and-cardiovascular-risk-factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.79849","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}